<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150914</url>
  </required_header>
  <id_info>
    <org_study_id>RLDC5713</org_study_id>
    <secondary_id>U01HL131755-01</secondary_id>
    <nct_id>NCT03150914</nct_id>
  </id_info>
  <brief_title>Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial</brief_title>
  <acronym>MILED</acronym>
  <official_title>Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The LAM Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine if early, long-term low dose sirolimus is effective for
      preventing progression to more advanced stages.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the MILED trial is to determine if early, long term (2 yr), low dose
      (fixed at 1 mg/day) treatment of patients with well-preserved lung function will prevent
      disease progression to more advanced stages. Sixty patients with FEV1&gt;70% predicted will be
      enrolled and randomized to receive 1 mg/day sirolimus or placebo, and followed for a period
      of 2 years with pulmonary function testing every 4 months. The primary endpoint will be the
      between-group (placebo vs. sirolimus) difference in the rate of change in FEV1 (in liters)
      over two years. Secondary endpoints will include severity grade adverse events, time to 200cc
      or 10% FEV1 decline, forced vital capacity, lung volumes, diffusing capacity, serum VEGF-D,
      and early airflow obstruction assessed using hyper-polarized gas MRI. The study will be
      conducted through the Rare Lung Disease Clinic Network, a confederacy of clinics organized by
      the LAM Foundation that is currently following over 1300 U.S. LAM patients and conducting the
      Department of Defense sponsored Trial of an Aromatase Inhibitor in LAM (TRAIL) trial. The LAM
      Foundation will assist with study recruitment and dissemination of results, and the
      University of South Florida will function as the Data Coordinating Center. Successful
      completion of this study will define the safety and efficacy of low dose sirolimus in
      patients with normal lung function, and determine if sirolimus can be used to prevent disease
      progression to symptomatic stages.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intention to treat, randomized, placebo controlled, double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Tablets are over-encapsulated. Both participant and care givers are blinded to treatment assignment. Dose adjustments for out of range sirolimus levels are made by a medical monitor at the Data Center. Sham dose adjustments are made in the placebo group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1 slope)</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of lung function decline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffusing Capacity for Carbon Monoxide (DLCO)</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of decline in diffusing capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity (TLC)</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of change in total lung capacity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Overencapsulated matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Over-encapsulated .5 mg or 1 mg sirolimus tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>mTOR inhibitor or placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, age 18 or over

          2. Signed and dated informed consent Diagnosis of LAM as determined by compatible lung CT
             and:1) biopsy (lung, abdominal mass, lymph node or kidney) or cytology from thoracic
             or abdominal sources revealing LAM, or 2) tuberous sclerosis, angiomyolipomata
             (diagnosed by CT, MRI by the site radiologist or biopsy) or chylous pleural effusion
             (verified by tap), or 3) VEGF-D level ≥ 800 pg/ml.

          3. Post-bronchodilator forced expiratory volume in one second of &gt; 70%

          4. Presence of markers of non-trivial burden of LAM or likely progression based on: 1)
             pretrial FEV 1 rate of decline of &gt;60cc/yr, comparing enrollment FEV1 to any prior
             measurement in the past 3 years, or 2) baseline supplemental oxygen requirement with
             exercise, or 3) premenopausal status or VEGF-D ≥ 600 pg/ml and any one of the
             following: A) baseline diffusing capacity for carbon monoxide ≤80% predicted, B)
             baseline residual volume ≥120% predicted, C) baseline desaturation by 4% or more on
             six minute walk testing on room air F) more than 20 cysts on the carinal cut of the CT

        Exclusion Criteria:

          1. Existing or imminent (within 12-18 months) clinical indication for treatment with mTOR
             inhibitors, based on judgment of site investigator

          2. DLCO &lt;60% predicted

          3. Resting room air saturation &lt;90%

          4. Exercise induced desaturation nadir on room air &lt; 85%

          5. History of myocardial infarction, angina or stroke related to atherosclerosis

          6. Pregnant, breast feeding, or plan to become pregnant in the next 2.5 years

          7. Inadequate contraception

          8. Significant hematologic, renal, metabolic or hepatic abnormality (i.e. transaminase
             levels &gt; three times the UL of normal range, HCT &lt; 30%, platelets &lt; 80,000/mm3,
             adjusted absolute neutrophil count &lt; 1,000/ mm3, total WBC &lt; 3,000/ mm3), creatinine
             &gt;2.5 mg/dl, uncontrolled hyperlipidemia

          9. Acute or chronic infection, such as (nontuberculous mucobacteria or active hepatitis B
             or C infections)

         10. Recent surgery (involving entry into a body cavity or requiring 3 or more sutures)
             within three weeks of initiation of study drug

         11. Use of sirolimus, everolimus or investigational treatment for LAM within the 30 days
             prior to randomization

         12. Previous lung transplantation or active on transplant list

         13. Inability to attend scheduled clinic visits, or perform pulmonary function testing

         14. Pleural effusion or chylous ascites sufficient to affect pulmonary function based on
             the opinion of the Site Investigator

         15. Acute pneumothorax within the past month

         16. History of malignancy in the past two years, other than squamous or basal cell skin
             cancer.

         17. Use of estrogen containing medications within the 30 days prior to randomization.

         18. Known allergy to sirolimus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis X. McCormack, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Univerisity of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan McMahan, BSN, RN</last_name>
    <phone>513-558-4376</phone>
    <email>susan.mcmahan@uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ruoss, M.D.</last_name>
      <phone>650-723-6381</phone>
      <email>ruoss@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Jewish Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206-2761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Downey, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Srihari Veeraraghavan, MD</last_name>
      <phone>404-778-5736</phone>
      <email>veeraraghavan@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Dilling, M.D.</last_name>
      <phone>708-216-4946</phone>
      <email>ddillin@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Woman's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth P Henske, M.D.</last_name>
      <phone>301-496-3632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Shifren, M.D.</last_name>
      <phone>314-362-6904</phone>
      <email>ashifren@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan McMahan</last_name>
      <phone>513-558-4376</phone>
      <email>susan.mcmahan@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Frank McCormack, M.D.</last_name>
      <phone>513-558-4831</phone>
      <email>frank.mccormack@uc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kotloff, M.D.</last_name>
      <phone>216-444-4222</phone>
      <email>kotlofr@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryl Kreider, M.D.</last_name>
      <phone>215-349-5488</phone>
      <email>KMaryElizabeth.Kreider@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Young, M.D.</last_name>
      <phone>615-343-4761</phone>
      <email>lisa.young@Vanderbilt.Edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Pappas, M.D.</last_name>
      <phone>206-320-6500</phone>
      <email>george.pappas@minorandjames.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Francis McCormack</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be publicly available once the study in published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

